Mode
Text Size
Log in / Sign up

Sulphur-handling gene program is lower in mesenchymal CMS4 colorectal cancer tumours than non-CMS4 tumoursSulphur-handling Genes Show Link to Specific Colorectal Cancer Types

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that the sulphur-handling programme is lower in CMS4 colorectal cancer, but no link to survival was found.

This meta-analysis analyzed 1,337 tumours from TCGA-COAD/READ cohorts and six HG-U133 validation cohorts to evaluate the association of a 14-gene sulphur-handling panel with consensus molecular subtypes (CMS) in colorectal cancer. The study identified a coordinated transcriptional programme involving the downregulation of SQOR, ETHE1, TST, CDO1, and CTH, alongside the selective upregulation of SLC7A11 and AHCY. The CBS gene was not significantly altered.

The primary finding indicates that this sulphur-handling programme score is consistently lower in mesenchymal CMS4 tumours than in non-CMS4 tumours. However, the analysis found no statistically detectable independent association between the sulphur-handling programme and overall, recurrence-free, or disease-free survival.

The authors note that the programme has not been fully explored functionally. While the study identifies SLC7A11/xCT inhibition as an exploratory candidate for preclinical testing, the evidence is currently limited to observational associations. Clinical application is currently restricted to preclinical research contexts.

How this fits prior evidence

This meta-analysis addresses a gap in understanding the molecular landscape of colorectal cancer subtypes. While previous evidence has explored the role of intestinal bacteria and their products in modulating Toll-like receptor signaling in colorectal cancer development, this study focuses on the specific transcriptional profile of the sulphur-handling programme. It provides a specific molecular signature for CMS4 tumours but does not currently provide evidence for clinical outcomes like survival or surgical success.

Researchers analyzed 1,337 tumors to study how certain genes handle sulphur. They looked specifically at how these genes behave in different types of colorectal cancer, known as consensus molecular subtypes. The study found that a specific group of genes was consistently lower in a specific subtype called CMS4 compared to other types.

While the study found a clear link between these sulphur-handling genes and specific cancer types, it did not find a link between these genes and how long patients lived or how often the cancer returned. This means the findings are about the biology of the tumor rather than a direct measure of patient outcomes.

Because this research is still in the early stages, these findings are not yet used to change how doctors treat patients. The study suggests that certain proteins could be studied further in a lab setting. These results are currently used for exploratory research rather than immediate clinical use.

What this means for you:
A specific group of sulphur-handling genes is linked to certain colorectal cancer types but does not affect survival.

Common questions

What did the study find about these genes and cancer?

The study found that a group of 14 genes involved in handling sulphur showed a specific pattern in colorectal cancer. Specifically, these genes were consistently lower in tumors labeled as CMS4 compared to other types. This helps researchers understand the biological differences between different types of colorectal cancer.

Does this mean these genes affect how long a patient lives?

No, the study did not find a statistically significant link between these sulphur-handling genes and overall survival, recurrence-free survival, or disease-free survival. While the genes are linked to specific cancer types, they did not show a direct impact on the length of time patients lived with the disease.

Can these findings be used to treat patients right now?

No, these findings are not yet used for clinical treatment. The study identified a specific protein as an exploratory candidate for preclinical testing. This means it is currently being studied in a lab setting to see if it could be a target for future treatments, but it is not a current medical recommendation.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
BackgroundColorectal cancer (CRC) exhibits substantial metabolic and transcriptomic heterogeneity, but the relationship between sulphur-handling transcriptional programmes and consensus molecular subtypes (CMS) remains incompletely resolved.MethodsWe analysed a predefined 14-gene sulphur-handling panel across The Cancer Genome Atlas colon and rectal adenocarcinoma cohorts (TCGA-COAD/READ) and six independent HG-U133 validation cohorts (n = 1,337 tumours). Analytical workflows integrated differential expression comparing tumours with adjacent-normal mucosa, CMS association modelling, random-effects meta-analysis, adjustment for three orthogonal tumour-purity estimators (ESTIMATE, consensus purity estimates, and ABSOLUTE), reference-based single-cell deconvolution with independent cross-atlas verification, and direction-aware therapeutic triage.ResultsColorectal tumours demonstrated branch-specific transcriptional alterations, marked by coordinated downregulation of sulphur oxidation and clearance genes (SQOR, ETHE1, TST) and of the cysteine-catabolism genes CDO1 and CTH, and selective upregulation of SLC7A11 and AHCY, whereas CBS was not significantly altered. The composite programme score differed across CMS subtypes and was consistently lower in mesenchymal CMS4 tumours than in non-CMS4 tumours across all discovery and validation series. This association remained statistically detectable after adjustment for three global tumour-purity metrics. The programme score showed no statistically detectable independent association with overall, recurrence-free, or disease-free survival. Single-cell deconvolution supported expression across epithelial, stromal, and immune compartments. Direction-aware therapeutic triage prioritised SLC7A11/xCT inhibition as an exploratory candidate for preclinical testing.ConclusionSulphur-handling transcriptional architecture is reproducibly linked to CRC molecular taxonomy and is not fully explained by measured tumour purity variation, providing a computational framework for future functional and compartment-resolved investigation of sulphur metabolism in stratified CRC populations.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.